#ICAD INVESTOR RELATIONS SOFTWARE#

We are looking for an enthusiastic intern to join our team and provide creative ideas to help achieve our goals. Closed: Marketing + Events Summer 2021 Intern For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at and on the SECвЂ™s website at. The Company is under no obligation to provide any updates to any information contained in this release. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The words вЂњbelieve,вЂќ вЂњdemonstrate,вЂќ вЂњintend,вЂќ вЂњexpect,вЂќ вЂњestimate,вЂќ вЂњwill,вЂќ вЂњcontinue,вЂќ вЂњanticipate,вЂќ вЂњlikely,вЂќ вЂњseek,вЂќ and similar expressions identify forward-looking statements. Such factors include, but are not limited, to the CompanyвЂ™s ability to achieve business and strategic objectives, the ability of IORT to alleviate the burden to our health system and minimize a patientвЂ™s potential exposure to Covid-19, to be more beneficial for patients that traditional therapy or to be accepted by patients or clinicians, the impact of supply and manufacturing constraints or difficulties, uncertainty of future sales levels, to defend itself in litigation matters, protection of patents and other proprietary rights, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence of products, increased competition, litigation and/or government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company and other risks detailed in the CompanyвЂ™s filings with the Securities and Exchange Commission. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. It uses a proprietary miniaturized x-ray source to deliver a precise, concentrated dose of radiation directly to the tumor site, while minimizing risk of damage to healthy tissue in nearby areas of the body.ДЇor more information, visit and Forward-Looking StatementsД¬ertain statements contained in this News Release constitute вЂњforward-looking statementsвЂќ within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the future prospects for the CompanyвЂ™s technology platforms and products. The Xoft System is FDA-cleared, CE marked and licensed in a growing number of countries for the treatment of cancer anywhere in the body. Additionally, ProFound AI for DBT improved radiologist sensitivity by 8 percent and reduced unnecessary patient recall rates by 7.2 percent. It offers clinically proven time-savings benefits to radiologists, including a reduction of reading time by 52.7 percent, thereby halving the amount of time it takes radiologists to read 3D mammography datasets.

#ICAD INVESTOR RELATIONS SOFTWARE#

In 2018, ProFound AI for Digital Breast Tomosynthesis (DBT) became the first artificial intelligence (AI) software for DBT to be FDA-cleared it was also CE marked and Health Canada licensed that same year. ProFound AIв„ў is a high-performing workflow solution for 2D and 3D mammography, or digital breast tomosynthesis (DBT), featuring the latest in deep-learning artificial intelligence. Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions.

Icad investor relations